AR053700A1 - Antagonistas del receptor de proquineticina 2 - Google Patents

Antagonistas del receptor de proquineticina 2

Info

Publication number
AR053700A1
AR053700A1 ARP060101154A ARP060101154A AR053700A1 AR 053700 A1 AR053700 A1 AR 053700A1 AR P060101154 A ARP060101154 A AR P060101154A AR P060101154 A ARP060101154 A AR P060101154A AR 053700 A1 AR053700 A1 AR 053700A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
phenyl
proviso
alkoxy
Prior art date
Application number
ARP060101154A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR053700A1 publication Critical patent/AR053700A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Composiciones farmacéuticos que los contienen y usos para el tratamiento de trastornos mediados por la proquineticina 2 o el receptor de proquineticina 2. Reivindicacion 1: Un compuesto de formula (1), donde: A1 es hidrogeno; arilo; heteroarilo; cicloalquilo C5-8; o heterociclilo; con la condicion de que A1 sea diferente de piridin-4-ilo, N-t-butoxicarbonil-piperidin-4-ilo, o N-metil-piperidin-3-ilo; y donde los sustituyentes de A1 diferentes de hidrogeno está opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6, halogeno, nitro, alquiloC1-6-halogenado, alcoxiC1-6-halogenado, alquiltio C1-6, alcoxiC1-6-carbonilo, amino, alquilamino C1-6, di(alquilC1-6)amino, ciano, hidroxi, aminocarbonilo, alquilamino, carbonilo C1-6, di(alquilC1-6)aminocarbonilo, alcoxiC1-6carbonilamino, alquilC1-6-carbonilo, alquiltioC1-6-carbonilo, formilo, alquilsulfonilo C1-6, alquilsulfonilamino C1-6, aminosulfonilo, alquilaminosulfonilo C1-6, y di(alquilC1-6)aminonsulfonilo; L1 es -(CH2)r- o -CH2CH2X(CH2)s-, opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, alquenilo C2-6, alquinilo C2-6, y halogeno; con la condicion de que cuando A1 es hidrogeno, r es mayor o igual a 4; r es un numero entero de 1 a 5; s es un numero entero de 1 a 3; X es O o S; D es -P-A2; donde cuando A2 es hidrogeno, P es -(CH2)4-6-, y cuando A2 es diferente de hidrogeno, P es -(CH2)1-2- o -CH2CH=CH-; A2 es hidrogeno; benzodioxalilo; heteroarilo diferente de piridin-2-ilo no sustituido; cicloalquilo C3-8; o fenilo opcionalmente sustituido en las posiciones meta y para con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, alcoxi C1-6, halogeno, alquilo C1-6-halogenado, alcoxiC1-6-halogenado, arilalcoxi C1-6, fenilo, alquiltio C1-6, alcoxiC1-6-carbonilo, amino, alquilamino C1-6, di(alquilC1-6)amino, ciano, hidroxi, nitro, alquilC1-6- carbonilo, alquiltioC1-6-carbonilo, aminocarbonilo, alquilaminoC1-6-carbonilo, di(alquilC1-6)aminocarbonilo, alquilC1-6-carbonilamino, y un cicloalquiloxi C3-6 no fusionado, donde benzodioxalilo, heteroarilo, y cicloalquilo C3-8 están opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, alcoxi C1-6, halogeno, alquiloC1-6-halogenado, alcoxiC1-6- halogenado, arilalcoxi C1-6, fenilo, alquiltio C1-6, alcoxiC1-6-carbonilo, amino, alquilamino C1-6, di(alquilC1-6)amino, ciano, hidroxi, nitro, alquilC1-6-carbonilo, alquiltioC1-6-carbonilo, aminocarbonilo, alquilaminoC1-6-carbonilo, di(alquilC1- 6)aminocarbonilo, alquilC1-6-carbonilamino y un cicloalquiloxi C3-6 no fusionado; con la condicion de que no más de dos sustituyentes de A2 sean arilalcoxi C1-6, fenilo o un cicloalquilo C3-6 no fusionado; con la condicion de que cuando A1 es fenilo no sustituido y L2 es -X1-CH(Rx)-(CRyRz)-, donde X1 es NH, y Rx, Ry y Rz son hidrogeno, A2 sea diferente de fenilo no sustituido; fenilo sustituido con arilalcoxi C1-6 o fenilo; o fenilo sustituido en la posicion meta con ciano; y, además con la condicion de que cuando A1 es fenilo no sustituido y L2 es -X1- CH(Rx)-(CRyRz)2-, donde X1 es NH y Rx, Ry y Rz son cada uno hidrogeno, A2 sea diferente de fenilo sustituido con metoxi; y con la condicion de que cuando A1 es 3,4-dicloro-fenilo y P es - CH2-, A2 sea diferente de fenilo sustituido en la posicion meta con trifluorometilo o trifluorometoxi; y además con la condicion de que cuando A1 es 3,4-dicloro-fenilo y P es -(CH2)2-, A2 sea diferente de 4-metoxi-fenilo; W es N o C(Rx); donde Rw es H o alquilo C1-2; L2 es un radical bivalente seleccionado del grupo que consiste en: pirrolidinilo o piperidinilo unido al anillo de triazina de formula (1) por medio de su átomo de nitrogeno, donde dicho pirrolidinilo o piperidinilo está sustituido con un átomo de carbono con -(CH2)0-2-; NH-cicloalquiloC5-7-(CH2)0-2-; con la condicion de que cuando cicloalquilo C5-7 es ciclohexilo, Q está unido a la posicion 2- o cis-4- en relacion con la posicion de -NH-; X1-alquiloC2-6-; X1-(CH2)u- X2-(CH2)v- ; donde u es un numero entero de 1 a 3; y donde v es un numero entero de 1 a 4; con la condicion de que cuando X1 es un enlace directo y W es C(Rw), entonces u es 1 y v es 2 a 4; X2-(CH2)0-4-; X1-(CH2)2-3-X3-(CH2)2-3-; NH(CH2)1-4C(=O)-, con la condicion de que al menos uno de Rb, Rc, o Rd es diferente de hidrogeno y m es 0; NHC(=O)-(CH2)1-4-; C(=O)NH(CRyRz)2-5-; y X1- CH(Rx)-(CRyRz)1-5-; de manera tal que cuando X1 es un enlace directo y W es C(Rw), entonces Rx es hidrogeno; donde X1 es - NH-, O, S, o un enlace directo, de manera tal que X1 es diferente de O cuando W es N; X2 es -CH=CH-; X3 es O, S, NH, o C=O; Rx, Ry, y Rz son independientemente H o alquilo C1-4; y con la condicion de que L2 en ningun caso exceda de 7 átomos de longitud; y además con la condicion de que cuando L2 es -X2-(CH2)0-4- o -C(=O)NH(CRyRz)2-5-, entonces Rw es hidrogeno; Q es (O)mN(Ra)-G; y m es 0 o 1; G es -C(=NRb)NRcRd; Ra y Rd son independientemente hidrogeno, alquilo C1-6, alquenilo C1-6 o alquinilo C3-6, donde los sustituyentes de Ra y Rd diferentes de hidrogeno están opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en hidroxi, alcoxi C1-4, fluoro, amino, alquilamino C1-4, dialquilamino C1-4, y alquilC1-4-carbonilo; o Ra y Rc se toman junto con los átomos a los cuales están unidos para formar un anillo monocíclico de 5-8 miembros opcionalmente sustituido con oxo; Rb es hidrogeno, alquilo C1-6, alquenilo C2-6, alquinilo C3-6, alcoxi C3-6-carbonilo, o ciano; o Rb y Rc se toman junto con los átomos a los cuales están unidos para formar un anillo monocíclico de 5-8 miembros, opcionalmente sustituido con oxo; Rc es hidrogeno, alquilo C1-10, alquenilo C2-10, alquinilo C3-10, cicloalquilo C3-7, adamantilo, amino, alquilamino C1-6, di(alquilC1-6)amino, alquilC1-6-carbonilo, alcoxiC1-6-carbonilo, arilcarbonilo, heteroarilcarbonilo, heterociclilcarbonilo, arilo, heteroarilo o heterociclilo; donde alquilo C1- 10, alquenilo C2-10, y alquinilo C2-10 están opcionalmente sustituidos con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en hidroxi, alcoxi C1-6, trifluorometilo, arilo, heteroarilo y heterociclilo; y donde cualquier sustituyente de Rc que contiene arilo o heteroarilo está opcionalmente sustituido con uno a tres sustituyentes seleccionados independientemente del grupo que consiste en alquilo C1-6, alcoxi C1-6, halogeno, alquilo C1-6-fluorado, alcoxiC1- 6-fluorado, alquilC1-6-carbonilo, alcoxiC1-6-carbonilo, aminocarbonilo, alquilaminoC1-6-carbonilo, di(alquilC1-6)aminocarbonilo, alcoxiC1-6- carbonilamino, formilo, alquilsulfonilo C1-6, alquilsulfonilamino C1-6, aminosulfonilo, alquilaminosulfonilo C1-6, y di(alquiloC1-6) aminosulfonilo, nitro, metiltio, hidroxi y ciano; o Rc y Rd se toman con los átomos a los cuales están unidos para formar un anillo monocíclico de 5-8 miembros que opcionalmente incluye 1 a 2 heteroátomos O o S en el anillo y dicho anillo está opcionalmente sustituido con oxo; con la condicion de que en cualquier caso, solo exista un anillo opcionalmente entre Ra y Rb, Rb y Rc, o Rc y Rd; y enantiomeros, diastereomeros, tautomeros, solvatos, y sus sales aceptables para uso farmacéutico.
ARP060101154A 2005-03-24 2006-03-23 Antagonistas del receptor de proquineticina 2 AR053700A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66486505P 2005-03-24 2005-03-24

Publications (1)

Publication Number Publication Date
AR053700A1 true AR053700A1 (es) 2007-05-16

Family

ID=36580484

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101154A AR053700A1 (es) 2005-03-24 2006-03-23 Antagonistas del receptor de proquineticina 2

Country Status (16)

Country Link
US (1) US20080045535A1 (es)
EP (1) EP1869006A1 (es)
JP (1) JP2008534499A (es)
KR (1) KR20070116915A (es)
CN (1) CN101223147A (es)
AR (1) AR053700A1 (es)
AU (1) AU2006229791A1 (es)
BR (1) BRPI0609317A2 (es)
CA (1) CA2602510A1 (es)
EA (1) EA200702062A1 (es)
IL (1) IL186188A0 (es)
MX (1) MX2007011847A (es)
NO (1) NO20075406L (es)
TW (1) TW200716566A (es)
WO (1) WO2006104713A1 (es)
ZA (1) ZA200709147B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006004712A2 (en) 2004-06-29 2006-01-12 United States Postal Service Cluster box mail delivery unit having security features
CN101326168A (zh) 2005-03-24 2008-12-17 詹森药业有限公司 激肽原1受体拮抗剂
US7855201B2 (en) * 2005-12-06 2010-12-21 Merck Sharp & Dohme. Corp. Morpholine carboxamide prokineticin receptor antagonists
CA2635845A1 (en) * 2005-12-29 2007-07-12 Janssen Pharmaceutica N.V. Prokineticin 2 receptor antagonists
CL2006003736A1 (es) * 2005-12-29 2008-05-16 Janssen Pharmaceutica Nv Compuestos derivados de triazina o pirimidina sustituida, antagonistas del receptor de prokineticina 1, composicion farmaceutica; y uso en el tratamiento de trastornos gastrointestinales.
WO2009058653A1 (en) * 2007-10-30 2009-05-07 Janssen Pharmaceutica N.V. Amino-heteroaryl-containing prokineticin 1 receptor antagonists
WO2010077976A2 (en) * 2008-12-17 2010-07-08 The Regents Of The University Of California Prokineticin receptor antagonists and uses thereof
EP2399910B1 (en) 2009-02-13 2014-04-02 Shionogi&Co., Ltd. Triazine derivatives as p2x3 and/or p2x2/3 receptor antagonists and pharmaceutical composition containing them
US8841447B2 (en) * 2009-03-26 2014-09-23 Mapi Pharma Ltd. Process for the preparation of alogliptin
WO2012006004A1 (en) * 2010-06-28 2012-01-12 Janssen Pharmaceutica Nv Prokineticin 1 receptor antagonists for the treatment of pain
EP2585068A1 (en) * 2010-06-28 2013-05-01 Janssen Pharmaceutica, N.V. Prokineticin 1 receptor antagonists for the treatment of pain
WO2012020742A1 (ja) 2010-08-10 2012-02-16 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
KR101867110B1 (ko) 2010-08-10 2018-06-12 시오노기 앤드 컴파니, 리미티드 트라이아진 유도체 및 그것을 함유하는 진통 작용을 갖는 의약 조성물
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
JP6358639B2 (ja) 2015-04-24 2018-07-18 塩野義製薬株式会社 ６員複素環誘導体およびそれらを含有する医薬組成物
MX2019004107A (es) 2016-10-17 2019-08-05 Shionogi & Co Derivado heterociclico nitrogenado biciclico y composicion farmaceutica que lo contiene.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704272D0 (sv) * 1997-11-21 1997-11-21 Astra Pharma Prod Novel Compounds
JP2006500351A (ja) * 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
JP2008534499A (ja) 2008-08-28
CA2602510A1 (en) 2006-10-05
EP1869006A1 (en) 2007-12-26
ZA200709147B (en) 2009-08-26
TW200716566A (en) 2007-05-01
MX2007011847A (es) 2008-03-11
NO20075406L (no) 2007-12-14
WO2006104713A1 (en) 2006-10-05
IL186188A0 (en) 2008-01-20
AU2006229791A1 (en) 2006-10-05
US20080045535A1 (en) 2008-02-21
EA200702062A1 (ru) 2008-02-28
BRPI0609317A2 (pt) 2010-03-16
CN101223147A (zh) 2008-07-16
KR20070116915A (ko) 2007-12-11

Similar Documents

Publication Publication Date Title
AR053700A1 (es) Antagonistas del receptor de proquineticina 2
AR053451A1 (es) Antagonistas del receptor de proquineticina 1
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AR058407A1 (es) Antagonistas del receptor de proquineticina 2
EA200601125A1 (ru) 6-замещённые циклогексилалкил 2-замещённые хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(adp-рибоза)полимеразы
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
AR048069A1 (es) Derivados de pirazolo con heteroarilo fusionado
AR069512A1 (es) Pirazolopirimidinas sustituidas para el tratamiento de trastornos del snc. composiciones farmaceuticas
UA89618C2 (ru) 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы
NO20074666L (no) Imidazo(1,2-A)pyridinforbindelser som VEGF-R2-inhibitorer
SE0301373D0 (sv) Novel compounds
TW200508212A (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
RS51445B (en) PYROLIDINDION SUBSTITUTED BY PIPERIDINE-PTHALAZONE AS PDE4 INHIBITORS
EA200801128A1 (ru) Пери-конденсированные трициклические соединения, полезные в качестве антибактериальных средств
AR069127A1 (es) Antagonistas del receptor de procineticina 1 que contienen amino-heteroarilo
DK1474395T3 (da) Nicotinamidderivater, der er nyttige som p38-inhibitorer
HK1110588A1 (en) Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
AR058406A1 (es) Antagonistas del receptor de proquineticina 1
AR049323A1 (es) Compuestos heterociclicos nitrogenados inhibidores de igf-1r y composiciones farmaceuticas que los componen.
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
HRP20080667T3 (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives the treatment of infertility
AR014173A1 (es) Compuestos inhibidores del intercambio sodio/protones, de acil guanidina, utiles como agentes antianginales y cardioprotectores y las composicionesfarmaceuticas que los contienen
EA200600018A1 (ru) Производные никотинамида, полезные в качестве ингибиторов фдэ4

Legal Events

Date Code Title Description
FA Abandonment or withdrawal